Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting

Swapnil Kumar, Reema Narayan, Vasif Ahammed, Yogendra Nayak, Anup Naha, Usha Y. Nayak

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The aim of the present study was to develop and evaluate solid lipid nanoparticles (SLNs) of anti-HIV drug ritonavir to target intestinal lymphatic vessels and bioavailability enhancement by the oral route of administration. SLNs were prepared by solvent evaporation followed by ultrasonication using Compritol 888 and sodium lauryl sulfate using Box Behnken design. SLNs were characterized for particle size, zeta potential, entrapment efficiency, in vitro release and pharmacokinetic studies. The average particle size for the optimized formulations was well within 300 nm, and PDI (0.361) and zeta potential (−32.4 mV) were also found to be in acceptable ranges. The encapsulation efficiency ranged from 53.20 ± 4.13 to 73.04 ± 2.85%. Scanning electron microscopy images indicated the complete dispersion of drug within the lipid structure. The less intense peaks at 2θ of 21.03° and 18.86° were observed in the XRD diffraction spectrum of SLNs indicating transformation into an amorphous form. The pharmacokinetic studies indicated that the extent of absorption for the solid lipid nanoparticles was found to be much higher in the spleen and thymus compared to that in the plasma which indicated that the developed formulations could enhance the bioavailability and intestinal lymphatic target specificity.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalJournal of Drug Delivery Science and Technology
Volume44
DOIs
Publication statusPublished - 01-04-2018

Fingerprint

Ritonavir
Nanoparticles
Lipids
Particle Size
Biological Availability
Pharmacokinetics
Anti-HIV Agents
Lymphatic Vessels
Sodium Dodecyl Sulfate
Electron Scanning Microscopy
Thymus Gland
Oral Administration
Spleen
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

@article{5227e219d7434bbba19f376125560ee6,
title = "Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting",
abstract = "The aim of the present study was to develop and evaluate solid lipid nanoparticles (SLNs) of anti-HIV drug ritonavir to target intestinal lymphatic vessels and bioavailability enhancement by the oral route of administration. SLNs were prepared by solvent evaporation followed by ultrasonication using Compritol 888 and sodium lauryl sulfate using Box Behnken design. SLNs were characterized for particle size, zeta potential, entrapment efficiency, in vitro release and pharmacokinetic studies. The average particle size for the optimized formulations was well within 300 nm, and PDI (0.361) and zeta potential (−32.4 mV) were also found to be in acceptable ranges. The encapsulation efficiency ranged from 53.20 ± 4.13 to 73.04 ± 2.85{\%}. Scanning electron microscopy images indicated the complete dispersion of drug within the lipid structure. The less intense peaks at 2θ of 21.03° and 18.86° were observed in the XRD diffraction spectrum of SLNs indicating transformation into an amorphous form. The pharmacokinetic studies indicated that the extent of absorption for the solid lipid nanoparticles was found to be much higher in the spleen and thymus compared to that in the plasma which indicated that the developed formulations could enhance the bioavailability and intestinal lymphatic target specificity.",
author = "Swapnil Kumar and Reema Narayan and Vasif Ahammed and Yogendra Nayak and Anup Naha and Nayak, {Usha Y.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.jddst.2017.12.014",
language = "English",
volume = "44",
pages = "181--189",
journal = "Journal of Drug Delivery Science and Technology",
issn = "1773-2247",
publisher = "Editions de Sante",

}

Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting. / Kumar, Swapnil; Narayan, Reema; Ahammed, Vasif; Nayak, Yogendra; Naha, Anup; Nayak, Usha Y.

In: Journal of Drug Delivery Science and Technology, Vol. 44, 01.04.2018, p. 181-189.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting

AU - Kumar, Swapnil

AU - Narayan, Reema

AU - Ahammed, Vasif

AU - Nayak, Yogendra

AU - Naha, Anup

AU - Nayak, Usha Y.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The aim of the present study was to develop and evaluate solid lipid nanoparticles (SLNs) of anti-HIV drug ritonavir to target intestinal lymphatic vessels and bioavailability enhancement by the oral route of administration. SLNs were prepared by solvent evaporation followed by ultrasonication using Compritol 888 and sodium lauryl sulfate using Box Behnken design. SLNs were characterized for particle size, zeta potential, entrapment efficiency, in vitro release and pharmacokinetic studies. The average particle size for the optimized formulations was well within 300 nm, and PDI (0.361) and zeta potential (−32.4 mV) were also found to be in acceptable ranges. The encapsulation efficiency ranged from 53.20 ± 4.13 to 73.04 ± 2.85%. Scanning electron microscopy images indicated the complete dispersion of drug within the lipid structure. The less intense peaks at 2θ of 21.03° and 18.86° were observed in the XRD diffraction spectrum of SLNs indicating transformation into an amorphous form. The pharmacokinetic studies indicated that the extent of absorption for the solid lipid nanoparticles was found to be much higher in the spleen and thymus compared to that in the plasma which indicated that the developed formulations could enhance the bioavailability and intestinal lymphatic target specificity.

AB - The aim of the present study was to develop and evaluate solid lipid nanoparticles (SLNs) of anti-HIV drug ritonavir to target intestinal lymphatic vessels and bioavailability enhancement by the oral route of administration. SLNs were prepared by solvent evaporation followed by ultrasonication using Compritol 888 and sodium lauryl sulfate using Box Behnken design. SLNs were characterized for particle size, zeta potential, entrapment efficiency, in vitro release and pharmacokinetic studies. The average particle size for the optimized formulations was well within 300 nm, and PDI (0.361) and zeta potential (−32.4 mV) were also found to be in acceptable ranges. The encapsulation efficiency ranged from 53.20 ± 4.13 to 73.04 ± 2.85%. Scanning electron microscopy images indicated the complete dispersion of drug within the lipid structure. The less intense peaks at 2θ of 21.03° and 18.86° were observed in the XRD diffraction spectrum of SLNs indicating transformation into an amorphous form. The pharmacokinetic studies indicated that the extent of absorption for the solid lipid nanoparticles was found to be much higher in the spleen and thymus compared to that in the plasma which indicated that the developed formulations could enhance the bioavailability and intestinal lymphatic target specificity.

UR - http://www.scopus.com/inward/record.url?scp=85039450538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039450538&partnerID=8YFLogxK

U2 - 10.1016/j.jddst.2017.12.014

DO - 10.1016/j.jddst.2017.12.014

M3 - Article

AN - SCOPUS:85039450538

VL - 44

SP - 181

EP - 189

JO - Journal of Drug Delivery Science and Technology

JF - Journal of Drug Delivery Science and Technology

SN - 1773-2247

ER -